Manuel Sánchez-Arjona
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Manuel Sánchez-Arjona has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ana Alarcón Tomás
Department of Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, Spain
1 shared publication - Ana Belén Bocanegra Pérez-Vizcaino
Department of Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, Spain
1 shared publication - Ana Fernández-Cruz
Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, Spain
1 shared publication - Andrea Gutiérrez-Villanueva
Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, Spain
1 shared publication - Claudia Gómez Nicolás
Department of Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, Spain
1 shared publication - Gabriela Rubial Carvajal
Department of Microbiology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, Spain
1 shared publication
Latest Publications
- Open Access
- 6 November 2026
- Published by MDPI AG in Preprints.org
Disseminated Histoplasmosis and Pneumocystis Coinfection in a Patient with Myelofibrosis on Ruxolitinib and Azacitidine: A Case Report
Ruxolitinib is a JAK1 and JAK2 inhibitor approved in 2011 for the treatment of myelofibrosis., It is unclear if this drug can increase the risk of fungal infections. We present the case of a 67-year-old man with post-polycythemia vera myelofibrosis under treatment with ruxolitinib and azacitidine admitted to the Hematology Department with a history of subacute constitutional syndrome and diarrhea followed by fever. Biopsies of oral and colonic ulcerated lesions revealed Histoplasma; and subsequent bronchoalveolar lavage (BAL) was also positive for Histoplasma and Pneumocystis. Treatment with amphotericin B and isavuconazole was initiated without discontinuing ruxolitinib, resulting in a favourable response, confirmed by PET/CT. This case highlights the potential association of invasive fungal infection (IFI) with ruxolitinib treatment, the risk of endemic opportunistic fungal infections and the usefulness of PET/CT for follow-up of disseminated IFI.
- 6 November 2026
- Published by MDPI AG in Preprints.org
Open AccessDisseminated Histoplasmosis and Pneumocystis Coinfection in a Patient with Myelofibrosis on Ruxolitinib and Azacitidine: A Case Report
Ruxolitinib is a JAK1 and JAK2 inhibitor approved in 2011 for the treatment of myelofibrosis., It is unclear if this drug can increase the risk of fungal infections. We present the case of a 67-year-old man with post-polycythemia vera myelofibrosis under treatment with ruxolitinib and azacitidine admitted to the Hematology Department with a history of subacute constitutional syndrome and diarrhea followed by fever. Biopsies of oral and colonic ulcerated lesions revealed Histoplasma; and subsequent bronchoalveolar lavage (BAL) was also positive for Histoplasma and Pneumocystis. Treatment with amphotericin B and isavuconazole was initiated without discontinuing ruxolitinib, resulting in a favourable response, confirmed by PET/CT. This case highlights the potential association of invasive fungal infection (IFI) with ruxolitinib treatment, the risk of endemic opportunistic fungal infections and the usefulness of PET/CT for follow-up of disseminated IFI.